source
- Curium to acquire Lantheus in deal valued up to $8 billionCurium announced it will purchase all outstanding shares of Lantheus for $102.50 cash per share, with potential additional $12 per share via contingent value rights linked to sales milestones in pr…
- Supernus and Indivior announce all-stock merger to create CNS-focused drugmakerSupernus Pharmaceuticals and Indivior Pharmaceuticals have signed an all‑stock merger agreement to combine their businesses. The new company will be dedicated to developing treatments for central…